Although the data are only from a small, open-label study, Morphic Therapeutic, Inc. generated excitement from shareholders and analysts on 25 April with top-line data showing its selective alpha-4 beta-7 (ɑ4β7) integrin inhibitor MORF-057 could offer similar efficacy in ulcerative colitis patients to Takeda Pharmaceutical Co. Ltd.’s injectable blockbuster Entyvio (vedolizumab), with a clean safety profile.
Morphic needed a win following the exits of AbbVie Inc. last June and Janssen Pharmaceutica Inc. in January from partnerships around its oral integrin inhibitor R&D platform. (Also see "Janssen Follows AbbVie To Exit From Morphic Deal, But Lead Asset Still Has Chance" - Scrip, 23 January, 2023
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?